Oncoholdings 认领应用

Oncoholdings, Inc. is a pharmaceutical company focused on the development and commercialization of promising new cancer therapies. Oncoholdings will acquire ownership of, controlling stakes in, or licensing agreements for differentiated and commercially attractive pharmaceutical products in the early stages of clinical trials when the promise of the therapy becomes apparent, and leverage its virtual development organization to progress their development and commercialization. The initial Oncoholdings product, Onco-101, is a selective inhibitor of HDAC-6 and is showing remarkable preclinical efficacy in platinum refractory ovarian and endometrial tumor models.